PharVision Advisers’s AGNT Inc AGNT Stock Holding History

PharVision Advisers’s Portfolio AGNT Stock Details AGNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-43,765	Closed	-$396K	–	288
2025 Q4	$396K	Buy	+43,765	New	+$462K	0.2%	130

Other funds holding AGNT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PharVision Advisers's AGNT Position: Q1 2026 in Review

PharVision Advisers sold out of AGNT Inc (AGNT) in Q1 2026, closing a stake of 43,765 shares — an estimated $396K sold.

PharVision Advisers first reported a position in AGNT in Q4 2025 and held it in 1 quarter. The position peaked at $396K in Q4 2025. 228 funds tracked by Wall St. Rank hold AGNT as of Q1 2026.

PharVision Advisers reported no remaining AGNT Inc position as of Q1 2026 after selling out during the quarter.
PharVision Advisers sold 43,765 AGNT Inc shares in Q1 2026, an estimated $396K.
PharVision Advisers first reported a position in AGNT Inc in Q4 2025 and held it in 1 quarter.
PharVision Advisers's AGNT Inc position peaked at $396K in Q4 2025.
228 funds tracked by Wall St. Rank held AGNT Inc as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.